Company: SMNR
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001193125-25-179226
Chunk: 0

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 0
---
Filed Pursuant to Rule 424(B)(3)
Registration No. 333-283019

PROXY STATEMENT FOR

EXTRAORDINARY GENERAL MEETING

OF DENALI CAPITAL ACQUISITION CORP.

(A CAYMAN ISLANDS EXEMPTED COMPANY)

PROSPECTUS FOR

292,476,239 SHARES OF COMMON STOCK, 524,622 UNITS

6,000,000 SHARES OF SERIES A PREFERRED STOCK, AND 8,760,000 WARRANTS

OF

DENALI CAPITAL ACQUISITION CORP.

(AFTER ITS DOMESTICATION AS A CORPORATION INCORPORATED IN THE STATE OF DELAWARE), WHICH WILL BE RENAMED “SEMNUR PHARMACEUTICALS, INC.” IN CONNECTION WITH THE BUSINESS COMBINATION DESCRIBED HEREIN

Dear Shareholders:

You are cordially invited to attend the extraordinary general meeting (the “Meeting”) of Denali Capital Acquisition Corp., a Cayman Islands exempted
company (“Denali”), at the offices of US Tiger Securities, Inc. located at 437 Madison Avenue, 27th Floor, New York, New York 10022, at 9:00 a.m. Eastern Time, on Wednesday, September 3, 2025.

Denali is a Cayman Islands exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase,
recapitalization, reorganization or other similar business transaction with one or more businesses or entities, which we refer to as a “target business.” Holders of Class A ordinary shares, par value $0.0001 per share, of Denali
(“Denali Class A Ordinary Shares”) and holders of Class B ordinary shares, par value $0.0001 per share, of Denali (“Denali Class B Ordinary Shares”), voting together as a single class, will be asked to approve and adopt the
Agreement and Plan of Merger, dated as of August 30, 2024 (as it may be amended or restated from time to time in accordance with its terms, including by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 16, 2025,
(“Amendment No. 1 to Merger Agreement”) and Amendment No. 2 to Agreement and Plan of Merger, dated as of July 22, 2025, (“Amendment No. 2 to Merger Agreement